A favorable trend in OS in the pembrolizumab group was also observed (HR 0.72, 95% CI 0.51-1.02; P=0.03) ( 42 ).
also in 1,335 other papers
Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.